Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma

J Cutan Med Surg. 2009 May-Jun;13(3):155-9. doi: 10.2310/7750.2008.08006.

Abstract

Background: Historically, patients with the consumptive coagulopathy Kasabach-Merritt syndrome (KMS) have been treated with systemic corticosteroids as first-line therapy, but many patients do not respond. Recently, there have been increasing reports of the use of the chemotherapeutic drug vincristine in these patients.

Objective: To report a case of a newborn with a kaposiform hemangioendothelioma (KHE) of the right leg associated with KMS treated successfully with vincristine and oral corticosteroids.

Methods: The patient's chart and the literature on the subject were reviewed using Medline and PubMed.

Results: Treatment with vincristine and corticosteroids lead to sustained shrinking of the tumor and correction of the thrombocytopenia and coagulopathy through 1 year of age. We believe this is the first report in the North American literature of corticosteroids and vincristine being used concomitantly as first-line therapy for KHE with KMS.

Conclusion: Vincristine and corticosteroids should be considered first-line treatment for KMS.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Biopsy
  • Blood Coagulation Disorders / complications
  • Blood Coagulation Disorders / drug therapy*
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use*
  • Hemangioendothelioma / complications
  • Hemangioendothelioma / drug therapy*
  • Hemangioendothelioma / pathology
  • Humans
  • Infant, Newborn
  • Skin / pathology*
  • Syndrome
  • Vincristine / administration & dosage
  • Vincristine / therapeutic use*
  • Xeroderma Pigmentosum / complications
  • Xeroderma Pigmentosum / drug therapy*
  • Xeroderma Pigmentosum / pathology

Substances

  • Antineoplastic Agents, Phytogenic
  • Glucocorticoids
  • Vincristine